Principal Financial Group Inc. Purchases 817,652 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Principal Financial Group Inc. boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 527.9% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 972,529 shares of the company’s stock after purchasing an additional 817,652 shares during the period. Principal Financial Group Inc.’s holdings in Amneal Pharmaceuticals were worth $12,089,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of AMRX. Spire Wealth Management raised its position in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Amneal Pharmaceuticals by 1.2% during the 4th quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after purchasing an additional 1,159 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Amneal Pharmaceuticals by 1.6% during the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock valued at $1,297,000 after purchasing an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Amneal Pharmaceuticals by 2.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares during the period. Finally, Comerica Bank grew its stake in Amneal Pharmaceuticals by 56.1% during the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares during the period. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director directly owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 17.30% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $17.92 on Friday. Amneal Pharmaceuticals, Inc. has a one year low of $7.66 and a one year high of $18.39. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of 47.16 and a beta of 1.26. The business has a 50-day simple moving average of $15.59 and a 200 day simple moving average of $14.07.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. On average, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, UBS Group increased their target price on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $16.60.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.